Exec committee member responsible for FP&A, Investor relations, Business development & Strategic decision support for the US Oncology portfolio (covering Solid tumors, Hematology, Cell Therapy and Radio Therapy)

Exec committee member responsible for Finance, Administration, Investor relations and IT aspects of the Radioligand Therapies Company, a subsidiary of Novartis

• Key member of Oncology Deal Committee, responsible for portfolio strategy and deal assessments • Led a 6-member global team, overseeing structuring and financial analysis of various deal constructs such as Licensing, Acquisitions, Divestitures, Patent litigations etc. • Presented over 100 transactions to the Novartis Global Deal Committee and the Board of Directors for approval and successfully completed over 20 strategic transactions in role.• Developed an in-house database to rank order internal and external assets based on objective criteria and scoring based on public information

• Regional head responsible for BD&L and Strategic initiatives in the AMAC region (a cluster of 79 countries covering Asia-Pacific, Middle East and Africa).• Conducted portfolio reviews in key markets and recommended deal constructs to augment top line growth. • Delivered >$500m in incremental sales through local commercial partnerships in 2016-17 (25% topline growth vs PY)

• Responsible for deal assessments and contract negotiations for entire Global Pharma Division• Deal constructs included Licensing, Divestiture, Co-Marketing, M&A etc• Presented over 50 transactions to the Deal committee chaired by Global CEO• Faculty member of Novartis Finance Academy, scored highest course ratings over 2 years

Head of Finance for a $1.4B Primary Care business unit. Member of Business unit executive team. Responsible for financial oversight, strategic decision making, talent development and P&L management.

Responsible for Licensing, Divestiture, Co-Marketing, Mergers & Acquisition for the US Pharma business. • Principal member of the contract negotiation team for major in-licensing deals• Worked across functional teams (marketing, finance, development, regulatory etc) • Developed deal valuation and impact on key business metrics• Key member of a Generics strategy team for the US Pharma business

• Head of Finance for a $1Bn US Mature Products business. • Trusted member and thought partner of the Franchise executive leadership. • Responsibilities included Financial Planning, Strategic Long Term Planning, BD&L, Business Process oversight ( Supply chain, manufacturing, resourcing etc.)

• Analyze life cycle profitability of key brands and resource allocation across US Pharma portfolio• Developed game theory analysis to prepare Cardiovascular TA for an upcoming launch in the diabetes space, presented to CEO (received Business excellence award)• Prepare monthly summary binder highlighting business performance for CEO review • Assessment, evaluation and proposal of Pricing Actions for North America

Structured a 2004 zero-based budget model for the Mass Market and Special Segment Field Forces for Novartis to determine Sales force budget for the year 2004 (approx $1Billion) and optimize field force investment across product portfolio.

Audit associate covering Manufacturing clients for Statutory audits